Impact of Chromatography in Peptide Quantitation by Hybrid LBA LC-MS/MS Workflows
Traditional ligand binding assays (LBA) as a method for quantification of biotherapeutics in biologics matrices are being coupled with liquid chromatography tandem mass spectrometry (LC–MS/MS) to obtain more specificity and increase linear dynamic range (LDR), thus creating hybrid LBA/LC–MS/MS methods. This hybrid workflow is more sensitive and consistent than traditional methods, which is critical in efficacy and safety testing.
With the focus on sample preparation and mass spectrometry, LC is often overlooked. However, chromatographic optimization for hybrid LBA/LC-MS/MS methods step can ensure a robust analysis. This seminar will discuss the importance of magnetic bead and chromatographic media selection for hybrid LBA/LC–MS/MS workflows.
Key Learning Objectives:
- Basic overview of the new gold standard in pharmacokinetics for large molecule- hybrid LBA LC-MS
- LC development space for peptide quantitation methods
- Improving robustness in sample preparation for peptide quantitation
Who Should Attend?
- Bionalytical chemists new to large molecule pharmacokinetics and biotransformation methods
- Laboratories transitioning away from ligand binding assay to mass spectrometry
- Anyone interested in practical sample preparation strategies to improve current LBA LC-MS/MS methods
Presenter: Brian Rivera (Product Manager, Bioseparations & Specialty LC, Phenomenex)
Brian Rivera is the Bioseparations and Specialty LC Product Manager. He has over 10 years of experience in separations sciences, specializing in protein characterization by size exclusion chromatography, intact protein analysis by reversed phase, and glycan mapping.
Presenter: Carrie Haslam (Associate Editor, Selectscience)
